Document ID: chunk:federal_register_of_legislation:F2025L00212:clause:1_4592
Version: federal_register_of_legislation:F2025L00212
Segment Type: clause
Provision Reference: sch 1 cl 4592
Character Range: 2169287–2170739

4592                                      SODIUM HYDROXYCITRATE                                                                    A         The requirements specified below apply to a medicine that contains the ingredient that is:
                                                                                                                                             - listed in the Register on or after 1 March 2025; or
                                                                                                                                             - released for supply on or after 1 March 2026.
                                                                                                                                             When for oral use, the following warning statement is required on the medicine label:
                                                                                                                                             'In very rare cases, sodium hydroxycitrate may harm the liver. Stop use and see a doctor if you have yellowing skin/eyes or unusual: fatigue, nausea, appetite loss, abdominal pain, dark urine, or itching.'
                                                                                                                                             Medicines containing sodium hydroxycitrate must not be directed for use in children, or in pregnant or lactating women.